Cardiovascular–Endocrine–Metabolic Medicine: Proposing a New Clinical Sub-Specialty Amid the Cardiometabolic Pandemic
Biomolecules · 05.03.2025 · 15 (3) · 373
DOI: 10.3390/biom15030373 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 05.03.2025. Verfasst von Nikolaos Theodorakis und 2 weiteren Autor:innen. Beteiligte Einrichtung: NT-CardioMetabolics, Clinic for Metabolism and Athletic Performance, 47 Tirteou Str., 17564 Palaio Faliro, Greece. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Endocrinology, Metabolic Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cardiovascular–Renal–Hepatic–Metabolic diseases are on the rise worldwide, creating major challenges for patient care and clinical research. Although these conditions share common mechanisms and often respond to similar treatments—such as lifestyle changes and newer cardiometabolic drugs (e.g., SGLT2 inhibitors, GLP-1 receptor agonists)—clinical management remains divided among multiple specialties. Recently proposed curricula in Cardiometabolic Medicine and Preventive Cardiology reflect an effort to address this fragmentation. In addition, recent studies reveal that hormonal deficiencies may increase cardiovascular risk and worsen heart failure, with emerging data showing that correcting these imbalances can improve exercise capacity and possibly reduce major cardiac events. To overcome gaps in care, we propose a new sub-specialty: Cardiovascular–Endocrine–Metabolic Medicine. This approach unifies three main pillars: (1) Lifestyle medicine, emphasizing nutrition, physical activity, and smoking cessation; (2) the Integrated Medical Management of obesity, diabetes, hypertension, dyslipidemia, heart failure with preserved ejection fraction, early-stage kidney disease, metabolic-associated liver disease, and related conditions; and (3) hormonal therapies, focused on optimizing sex hormones and other endocrine pathways to benefit cardiometabolic health. By bridging cardiology, endocrinology, and metabolic medicine, this sub-specialty offers a more seamless framework for patient care, speeds up the adoption of new treatments, and sets the stage for innovative research—all critical steps in addressing the escalating cardiometabolic pandemic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- NT-CardioMetabolics, Clinic for Metabolism and Athletic Performance, 47 Tirteou Str., 17564 Palaio Faliro, Greece.
- Department of Cardiology & Preventive Cardiology Outpatient Clinic, Amalia Fleming General Hospital, 14, 25th Martiou Str., 15127 Melissia, Greece.
- School of Medicine, National and Kapodistrian University of Athens, 75 Mikras Asias, 11527 Athens, Greece.
- School of Life Course & Population Health Sciences, King's College London, London WC2R 2LS, UK.
ORCID-Profile: Nikolaos Theodorakis, Maria Nikolaou
Zitieren
APA
Theodorakis, N., Nikolaou, M., & Krentz, A. (2025). Cardiovascular–Endocrine–Metabolic Medicine: Proposing a New Clinical Sub-Specialty Amid the Cardiometabolic Pandemic. Biomolecules, 15(3), 373. https://doi.org/10.3390/biom15030373
Vancouver
Theodorakis N, Nikolaou M, Krentz A. Cardiovascular–Endocrine–Metabolic Medicine: Proposing a New Clinical Sub-Specialty Amid the Cardiometabolic Pandemic. Biomolecules. 2025;15(3):373. doi:10.3390/biom15030373
BibTeX
@article{Theodorakis2025,
author = {Theodorakis, Nikolaos and Nikolaou, Maria and Krentz, Andrew},
title = {Cardiovascular–Endocrine–Metabolic Medicine: Proposing a New Clinical Sub-Specialty Amid the Cardiometabolic Pandemic},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {3},
pages = {373},
doi = {10.3390/biom15030373}
}
EUVIMED